Physician profile
Brian M Gotkin
NPI 1891782926
$6,925.42
in general payments reported to CMS, 2019-2025
22 companies · $3,010 in 2025
The $3,010 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,076 · 2020: $143 · 2021: $151 · 2022: $281 · 2023: $153 · 2024: $111 · 2025: $3,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,910 · Food and Beverage: $246 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,910.00 |
| Food and Beverage | $246.08 |
| Education | $118.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,156.54 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,399.48 | 2019-2024 | |
| Glaxosmithkline, LLC. | $664.57 | 2019-2022 | |
| Genentech USA, INC. | $272.63 | 2019 | |
| Harmony Biosciences LLC | $228.48 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.95 | 2019 | |
| Insmed, INC. | $183.62 | 2019 | |
| Grifols USA, LLC | $173.88 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $109.63 | 2019 | |
| Advanced Respiratory, INC | $86.73 | 2019 | |
| Mylan Specialty L.P. | $80.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.57 | 2019-2023 | |
| Philips North America LLC | $54.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.29 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.38 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $36.32 | 2019 | |
| Mallinckrodt Enterprises LLC | $25.56 | 2019 | |
| Ambu INC. | $23.81 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.66 | 2019 | |
| Janssen Biotech, INC. | $16.44 | 2024 | Rybrevant |
| Pfizer INC. | $15.65 | 2019 | |
| Csl Behring | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gotkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.